Die molekulare Neurobiologie schizophrener Psychosen

M. Zink; A. Meyer-Lindenberg

doi:10.1055/s-0038-1626940

Nervenheilkunde, Table of Contents

Nervenheilkunde 2007; 26(10): 882-890
DOI: 10.1055/s-0038-1626940

Arbeiten zum Schwerpunkt - Theme Articles

Schattauer GmbH

Die molekulare Neurobiologie schizophrener Psychosen

Molecular neurobiology of schizophrenia

M. Zink

¹Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie (Ärztlicher Direktor: Prof. Dr. A. Meyer-Lindenberg)

,

A. Meyer-Lindenberg

¹Zentralinstitut für Seelische Gesundheit, Klinik für Psychiatrie und Psychotherapie (Ärztlicher Direktor: Prof. Dr. A. Meyer-Lindenberg)

²Unit of System Neuroscience in Psychiatry, National Institute of Mental Health, Bethesda, Maryland, USA

› Author Affiliations

Abstract

Zusammenfassung

Bereits in der griechischen Antike wurde formuliert, dass psychiatrischen Erkrankungen stoffliche Veränderungen zugrunde liegen. Pharmakologisch definierte pathogenetische Konzepte der Schizophrenie ergaben sich aus der Beobachtung, dass dopaminerge und anti-glutamaterge Substanzen psychotomimetisch, Dopaminantagonisten aber antipsychotisch wirken. Mit post-mortem-Studien konnten zelluläre und molekulare Veränderungen im Sinne einer Hirnentwicklungsstörung nachgewiesen werden. Aufbauend auf stabilen Befunden klassischer Genetik gelang es mittels Kopplungsanalysen und Assoziationsstudien, chromosomale Regionen und Kandidatengene wie Dysbindin, Neuregulin und COMT zu definieren. Verschiedene Tiermodelle erlaubten die Überprüfung molekularer Hypothesen. Mithilfe von Befunden der Neuropsychologie, der strukturellen und funktionellen Magnetresonanztomografie (fMRT), kann an neurogenetisch charakterisierten Probanden der Einfluss molekulargenetischer Variationen auf die Hirnfunktion in vivo molekular untersucht werden. Die Kombination der neurobiologischen Methoden verbessert das pathogenetische Verständnis schizophrener Psychosen und kann helfen, neue Therapieformen zu etablieren.

Summary

Neurobiological theories about the molecular pathogenesis of psychotic disorders were first developed in the Hippocratic opus “The sacred disease”. Pharmacological concepts of schizophrenia were guided by observations of psychotomimetic effects of dopaminergic or anti-glutamatergic substances, whereas antidopaminergic agents were antipsychotic. In parallel, neuropathological investigations accumulated evidence in favour of a neurodevelopmental theory of schizophrenia. A set of chromosomal regions linked to increased disease risk were defined by neurogenetic studies and many candidate genes such as dysbindin, neuregulin und COMT were reported. As a tool to test molecular hypotheses, several animal models were established. Neuropsychology, structural and functional magnetic resonance tomography (fMRT) do not reacha molecular resolution. However, the impact of genetic variation on neural function can be studied using translational imaging genetics. In conclusion, the combination of several neurobiological methods improves our knowledge of the pathogenesis of schizophrenia and can facilitate the development of innovative treatment approaches.

Schlüsselwörter

Magnetresonanztomografie - Neurobiologie - Neurogenetik - Pathogenese - Schizophrenie

Keywords

Magnetic resonance tomography - neurobiology - neurogenetics - pathogenesis - schizophrenia

Full Text

References

Literatur
1 Turnbull J, Lohi H, Kearney JA, Rouleau GA, gado-Escueta AV, Meisler MH. et al. Sacred disease secrets revealed: the genetics of human epilepsy. Hum Mol Gen 2005; 14: 2491-2500.
2 Sedivec V. Mental disorders in the writings of Hippocrates. Ceskoslovenska Psychiatrie 1989; 85: 270-273.
3 Tolle R. Wilhelm Griesingers “Magna Charta” of psychiatry. Its reception and impact on modern psychiatry. Fortschr Neurol Psychiatrie 2002; 70: 613-619.
4 Levitt P. Developmental neurobiology and clinical disorders: Lost in translation?. Neuron 2005; 46: 407-412.
5 Schumacher J, Jamra RA, Freudenberg J, Becker T, Ohlraun S, Otte AC. et al. Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Mol Psychiatry 2004; 09: 203-207.
6 Hattori E, Liu C, Badner JA, Bonner TI, Christian SL, Maheshwari M. et al. Polymorphisms at the G72/G30 gene locus, on 13q33, are associated with bipolar disorder in two independent pedigree series. Am J Hum Gen 2003; 72: 1131-1140.
7 Chumakov I, Blumenfeld M, Guerassimenko O, Cavarec L, Palicio M, Abderrahim H. et al. Genetic and physiological data implicating the new human gene G72 and the gene for D-amino acid oxidase in schizophrenia. Proc Nat Acad Sci USA 2002; 99: 13675-13680.
8 Ross CA, Margolis RL, Reading SA, Pletnikov M, Coyle JT. Neurobiology of schizophrenia. Neuron 2006; 52: 139-153.
9 Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
10 Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the “two hit hypothesis”. J Psychiatric Res 1999; 33: 543-548.
11 Benes FM. Why does psychosis develop during adolescence and early adulthood?. Curr Op Psychiatry 2003; 16: 317-319.
12 Mehler C, Warnke A. Structural brain abnormalities specific to childhood-onset schizophrenia identified by neuroimaging techniques. J Neur Transm 2002; 109: 219-234.
13 Rapaport JL, Evans A. Progressive cortical change during adolescence in childhood-onset schizophrenia. Arch Gen Psychiatry 1999; 56: 649-654.
14 Carlsson ML, Carlsson A, Nilsson M. Schizophrenia: from dopamine to glutamate and back. Curr Med Chem 2004; 11: 267-277.
15 Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M. et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nature Neurosci 2002; 05: 267-271.
16 Carlsson A, Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006; 39 (Suppl. 01) S10-S14.
17 Henn FA. The NMDA-receptor as a site for pathogenesis. Arch Gen Psychiatry 1995; 52: 1008-1010.
18 Konradi C, Heckers S. Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol Therapeutics 2003; 97: 153-179.
19 Marino MJ, Conn PJ. Direct and indirect modulation of the N-methyl D-aspartate receptor. Curr Drug Targets – CNS Neurol Disorders 2002; 01: 1-16.
20 Sur C, Kinney GG. The therapeutic potential of glycine transporter-1 inhibitors. Exp Op Invest Drugs 2004; 13: 515-521.
21 Carlsson A, Hansson LO, Waters N, Carlsson ML. A glutamatergic deficiency model of schizophrenia. Br J Psychiatry 1999; 174: 2-6.
22 Farber NB. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 2003; 1003: 119-130.
23 Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML. Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Ann Rev Pharmacol Toxicol 2001; 41: 237-260.
24 Harrison PJ. The neuropathology of schizophrenia. Brain 1999; 122: 593-624.
25 Jakob H, Beckmann H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neur Transm 1986; 65: 303-326.
26 Falkai P, Schneider-Axmann T, Honer WG. Entorhinal cortex pre-alpha cell clusters in schizophrenia: quantitative evidence of a developmental abnormality. Biol Psychiatry 2000; 47: 937-943.
27 Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry 1987; 44: 608-616.
28 Pierri JN, Chaudry AS, Woo T-UW, Lewis DA, Woo TU. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 1999; 156: 1709-1719.
29 Rioux L, Nissanov J, Lauber K, Bilker WB, Arnold SE. Distribution of microtubule-associated protein MAP2– immunoreactive interstitial neurons in the parahippocampal white matter in subjects with schizophrenia. Am J Psychiatry 2003; 160: 149-155.
30 Akil M, Lewis DA. Cytoarchitecture of the entorhinal cortex in schizophrenia. Am J Psychiatry 1997; 154: 1010-1012.
31 Krimer LS, Herman MM, Saunders RC, Boyd JC, Hyde TM, Carter JM. et al. A qualitative and quantitative analysis of the entorhinal cortex in schizophrenia. Cerebral Cortex 1997; 07: 732-739.
32 Jones LB. Loss of spines and neuropil. Int Rev Neurobiol 2004; 59: 1-18.
33 Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: a circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
34 Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 2000; 28: 53-67.
35 Sugai T, Kawamura M, Iritani S, Araki K, Makifuchi T, Imai C. et al. Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann NY Acad Sci 2004; 1025: 84-91.
36 Lehrmann E, Hyde TM, Vawter MP, Becker KG, Kleinman JE, Freed WJ. The use of microarrays to characterize neuropsychiatric disorders: postmortem studies of substance abuse and schizophrenia. Curr Mol Med 2003; 03: 437-446.
37 Katsel P, Davis KL, Gorman JM, Haroutunian V. Variations in differential gene expression patterns across multiple brain regions in schizophrenia. Schizophr Res 2005; 77: 241-252.
38 Arguello PA, Gogos JA. Modeling madness in mice: one piece at a time. Neuron 2006; 52: 179-196.
39 Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol Psychiatry 2001; 50: 845-855.
40 Zink M, Schmitt A, May B, Müller B, Demirakca T, Braus DF. et al. Differential effects of long-term treatment with clozapine of haloperidol on GABAa receptor binding and GAD67 expression. Schizophr Res 2004; 66: 151-157.
41 Zink M, Schmitt A, May B, Müller B, Braus DF, Henn FA. Differential effects of long-term treatment with clozapine or haloperidol on GABAtransporter expression. Pharmacopsychiatry 2004; 37: 171-174.
42 Levine M, Davidson EH. Gene regulatory networks for development. Proc Nat Acad Sci USA 2005; 102: 4936-4942.
43 Kriegstein AR, Noctor SC. Patterns of neuronal migration in the embryonic cortex. Trends Neurosci 2004; 27: 392-399.
44 Levitt P, Eagleson KL, Powell EM. Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders. Trends Neurosci 2004; 27: 400-406.
45 Vanderhaeghen P, Polleux F. Developmental mechanisms patterning thalamocortical projections: intrinsic, extrinsic and in between. Trends Neurosci 2004; 27: 384-391.
46 Molnar Z. Conserved developmental algorithms during thalamocortical circuit formation in mammals and reptiles. Novartis Foundation Symposium 2000; 228: 148-166.
47 Sherwood CC, Holloway RL, Semendeferi K, Hof PR. Is prefrontal white matter enlargement a human evolutionary specialization?. Nature Neurosci 2005; 08: 537-538.
48 Sun T, Patoine C, bu-Khalil A, Visvader J, Sum E, Cherry TJ. et al. Early asymmetry of gene transcription in embryonic human left and right cerebral cortex. Science 2005; 308: 1794-1798.
49 Van Den Buuse M, Garner B, Koch M. Neurodevelopmental animal models of schizophrenia: effects on prepulse inhibition. Curr Mol Med 2003; 03: 459-471.
50 Dalman C, Allebeck P, Cullberg J, Grunewald C, Köster M. Obstetric complications and the risk of schizophrenia. Arch Gen Psychiatry 1999; 56: 234-240.
51 Mallard EC, Rehn A, Rees S, Tolcos M, Copolov M. Ventriculomegaly and reduced hippocampal volume following intrauterine growth-restriction: implications for the aetiology of schizophrenia. Schizophr Res 1999; 40: 11-21.
52 Rehn AE, Van Den Buuse M, Copolov D, Briscoe T, Lambert G, Rees S. An animal model of chronic placental insufficiency: relevance to neurodevelopmental disorders including schizophrenia. Neurosci 2004; 129: 381-391.
53 Juarez I, Silva-Gomez AB, Peralta F, Flores G. Anoxia at birth induced hyperresponsiveness to amphetamine and stress in postpubertal rats. Brain Res 2003; 992: 281-287.
54 Schmitt A, Starke M, Ebert U, Zink M, Henn FA, Braus DF. Effects of postnatal hypoxia on NMDA receptor binding and gene expression of subunits as an animal model for obstetric complications in the pathophysiology of schizophrenia. Schizophr Res 2003; 60: 115.
55 Lipska BK. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 2004; 29: 282-286.
56 Lipska BK, Lerman DN, Khaing ZZ, Weinberger DR. The neonatal ventral hippocampal lesion model of schizophrenia: effects on dopamine and GABA mRNA markers in the rat midbrain. Eur J Neurosci 2003; 18: 3097-3104.
57 Jay TM, Rocher C, Hotte M, Naudon L, Gurden H, Spedding M. Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: importance for psychiatric diseases. Neurotox Res 2004; 06: 233-244.
58 Gelowitz DL, Rakic P, Goldman-Rakic PS, Selemon LD. Craniofacial dysmorphogenesis in fetally irradiated nonhuman primates: implications for the neurodevelopmental hypothesis of schizophrenia. Biol Psychiatry 2002; 52: 716-720.
59 Schneider M, Koch M. Deficient social and play behavior in juvenile and adult rats after neonatal cortical lesion: effects of chronic pubertal cannabinoid treatment. Neuropsychopharmacol 2005; 30: 944-957.
60 Sanchez-Huerta L, Ayala G, Marroquin J, Calderon R, Silva-Gomez AB, Khotiaintsev KS. et al. Neonatal prefrontal cortex lesion using CO2 laser technique. Brain Res Prot 2002; 02: 69-74.
61 Lavin A, Moore HM, Grace AA. Prenatal disruption of neocortical development alters prefrontal cortical neuron responses to dopamine in adult rats. Neuropsychopharmacol 2005; 30: 1426-1435.
62 Degen SB, Verheij MM, Cools AR. Genetic background, nature of event, and time of exposure to event direct the phenotypic expression of a particular genotype. A study with apomorphine-(un)susceptible Wistar rats. Beh Brain Res 2004; 154: 107-112.
63 Breese GR, Knapp DJ, Criswell HE, Moy SS, Papadeas ST, Blake BL. The neonate-6-hydroxydopamine-lesioned rat: a model for clinical neuroscience and neurobiological principles. Brain Res Rev 2005; 48: 57-73.
64 Tenn CC, Fletcher PJ, Kapur S. Amphetaminesensitized animals show a sensorimotor gating and neurochemical abnormality similar to that of schizophrenia. Schizophr Res 2003; 64: 103-114.
65 Tenn CC, Fletcher PJ, Kapur S. A putative animal model of the “prodromal” state of schizophrenia. Biol Psychiatry 2005; 57: 586-593.
66 Moghaddam B, Jackson ME. Glutamatergic animal models of schizophrenia. Ann NY Acad Sci 2003; 1003: 131-137.
67 Gainetdinov RR, Mohn AR, Caron MG. Genetic animal models: focus on schizophrenia. Trends Neurosci 2001; 24: 527-533.
68 Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436.
69 Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 2001; 21: 750-757.
70 Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS. et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Nat Acad Sci USA 2004; 101: 8485-8490.
71 Wood GK, Tomasiewicz H, Rutishauser U, Magnuson T, Quirion R, Rochford J. et al. NCAM-180 knockout mice display increased lateral ventricle size and reduced prepulse inhibition of startle. NeuroReport 1998; 16: 461-466.
72 Harrison SM, Reavill C, Brown G, Brown JT, Cluderay JE, Crook B. et al. LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Mol Cell Neurosci 2003; 24: 1170-1179.
73 Pickard BS, Pieper AA, Porteous DJ, Blackwood DH, Muir WJ. The NPAS3 gene--emerging evidence for a role in psychiatric illness. Ann Med 2006; 38: 439-448.
74 Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facialsyndrome. Arch Gen Psychiatry 1999; 56: 940-945.
75 Maynard TM, Haskell GT, Peters AZ, Sikich L, Lieberman JA, LaMantia AS. A comprehensive analysis of 22q11 gene expression in the developing and adult brain. Proc Nat Acad Sci USA 2003; 100: 14433-14438.
76 Jerome LA, Papaioannou VE. DiGeorge syndrome phenotype in mice mutant for the T-box gene, Tbx1. Nature Gen 2001; 27: 286-291.
77 Guris DL, Fantes J, Tara D, Druker BJ, Imamoto A. Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome. Nature Gen 2001; 27: 293-298.
78 Paterlini M, Zakharenko SS, Lai WS, Qin J, Zhang H, Mukai J. et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nature Neurosci 2005; 08: 1586-1594.
79 Tremolizzo L, Carboni G, Ruzicka WB, Mitchell CP, Sugaya I, Tueting P. et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc NatAcad Sci USA 2002; 99: 17095-17100.
80 Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ. et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006; 314: 140-143.
81 Potvin S, Stip E, Roy J-Y. Toxic psychoses as pharmacological models of schizophrenia. Curr Psychiatry Rev 2005; 01: 23-32.
82 Svenningsson P, Nairn AC, Greengard P. DARPP-32 mediates the actions of multiple drugs of abuse. AAPS Journal 2005; 07: E353-E360.
83 Konradi C, Cole RL, Heckers S, Hyman SE. Amphetamine regulates gene expression in rat striatum via transcription factor CREB. J Neurosci 1994; 14: 5623-5634.
84 Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH. et al. Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 2007; 117: 672-682.
85 Franzek E, Beckmann H. Different genetic background of schizophrenia spectrum psychoses: a twin study. AmJ Psychiatry 1998; 155: 76-83.
86 Maier W. Durchbruch in der Ursachenforschung bei der Schizophrenie. Nervenheilkunde 2007; 26: 377-380.
87 Levinson DF. Molecular genetics of schizophrenia: a review of the recent literature. Curr Op Psychiatry 2003; 16: 157-170.
88 van Amelsvoort T, Henry J, Morris R, Owen M, Linszen D, Murphy K. et al. Cognitive deficits associated with schizophrenia in velo-cardiofacial syndrome. Schizophr Res 2004; 70: 223-232.
89 Sobin C, Kiley-Brabeck K, Karayiorgou M. Lower prepulse inhibition in children with the 22q11 deletion syndrome. Am J Psychiatry 2005; 162: 1090-1099.
90 Gothelf D, Eliez S, Thompson T, Hinard C, Penniman L, Feinstein C. et al. COMT genotype predicts longitudinal cognitive decline and psychosis in 22q11.2 deletion syndrome. Nature Neurosci 2005; 08: 1500-1502.
91 Barnea-Goraly N, Menon V, Krasnow B, Ko A, Reiss A, Eliez S. Investigation of white matter structure in velocardiofacial syndrome: a diffusion tensor imaging study. Am J Psychiatry 2003; 160: 1863-1869.
92 van Amelsvoort T, Daly E, Henry J, Robertson D, Ng V, Owen M. et al. Brain anatomy in adults with velocardiofacial syndrome with and without schizophrenia: preliminary results of a structural magnetic resonance imaging study. Arch Gen Psychiatry 2004; 61: 1085-1096.
93 Bish JP, Nguyen V, Ding L, Ferrante S, Simon TJ. Thalamic reductions in children with chromosome 22q11.2 deletion syndrome. NeuroReport 2004; 15: 1413-1415.
94 Straub RE, Jiang Y, MacLean CJ, Ma Y, Webb BT, Myakishev MV. et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Gen 2002; 71: 337-348.
95 Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E. et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Gen 2003; 72: 83-87.
96 Straub RE, Weinberger DR. Schizophrenia genes – famine to feast. Biol Psychiatry 2006; 60: 81-83.
97 Morris JA, Kandpal G, Ma L, Austin CP. DISC1 (Disrupted-In-Schizophrenia 1) is a centrosomeassociated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Hum Mol Gen 2003; 12: 1591-1608.
98 Hennah W, Varilo T, Kestila M, Paunio T, Arajarvi R, Haukka J. et al. Haplotype transmission analysis provides evidence of association for DISC1 to schizophrenia and suggests sex-dependent effects. Hum Mol Gen 2003; 12: 3151-3159.
99 Callicott JH, Straub RE, Pezawas L, Egan MF, Mattay VS, Hariri AR. et al. Variation in DISC1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Nat Acad Sci USA 2005; 102: 8627-8632.
100 Egan MF, Straub RE, Goldberg TE, Yakub I, Callicott JH, Hariri AR. et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Nat Acad Sci USA 2004; 101: 12604-12609.
101 Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. Disease-specific changes in regulator of G-protein signalling 4 (RSG4) expression in schizophrenia. Mol Psychiatry 2005; 06: 293-301.
102 Gogos JA, Santha M, Takacs Z, Beck KD, Luine V, Lucas LR. et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nature Gen 1999; 21: 434-439.
103 Li W, Zhang Q, Oiso N, Novak EK, Gautam R, O’Brien EP. et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nature Gen 2003; 35: 84-89.
104 Burdick KE, Goldberg TE, Funke B, Bates JA, Lencz T, Kucherlapati R. et al. DTNBP1 genotype influences cognitive decline in schizophrenia. Schizophr Res 2007; 89: 169-172.
105 Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE. et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Nat Acad Sci USA 2001; 98: 6917-6922.
106 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK. et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825-844.
107 Adler LE, Freedman R, Ross RG, Olincy A, Waldo MC. Elementary phenotypes in the neurobiological and genetic study of schizophrenia. Biol Psychiatry 1999; 46: 8-18.
108 Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-645.
109 Wolkin A, Rusinek H, Vaid G, Arena L, Lafargue T, Sanfilipo M. et al. Structural magnetic resonance image averaging in schizophrenia. Am J Psychiatry 1998; 155: 1064-1073.
110 Woods BT, Ward KE, Johnson EH. Meta-analysis of the time-course of brain volume reduction in schizophrenia: implications for pathogenesis and early treatment. Schizophr Res 2005; 73: 221-228.
111 Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry 2003; 53: 412-421.
112 DeLisi LE, Hoff AL. Failure to find progressive temporal lobe volume decreases 10 years subsequent to a first episode of schizophrenia. Psychiatry Res 2005; 138: 265-268.
113 Kubicki M, McCarley RW, Shenton ME. Evidence for white matter abnormalities in schizophrenia. Curr Op Psychiatry 2005; 18: 121-134.
114 Curtis VA, Mcguire PK. Attenuated frontal activation during a verbal fluenca task in patients with schizophrenia. Am J Psychiatry 1998; 155: 1056-1063.
115 Perry W, Swerdlow NR, McDowell JE, Braff D. Schizophrenia and frontal lobe functioning: Evidence from neuropsychology, cognitive neuroscience, and psychophysiology. In, Cummings J, Miller B. (eds). The Frontal Lobes 1998; 509-521.
116 Callicott JH, Mattay VS, Verchinski BA, Marenco S, Egan MF, Weinberger DR. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry 2003; 160: 2209-2215.
117 Berman KF, Illowsky BP, Weinberger DR. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. Arch Gen Psychiatry 1988; 45: 616-622.
118 Wolf RC, Vasic N, Hoese A, Spitzer M, Walter H. Changes over time in frontotemporal activation during a working memory task in patients with schizophrenia. Schizophr Res 2007; 91: 141-150.
119 Walter H, Vasic N, Hoese A, Spitzer M, Wolf RC. Working memory dysfunction in schizophrenia compared to healthy controls and patients with depression: Evidence from event-related fMRI. Neuroimage 2007; 35: 1551-1561.
120 Heckers S, Rauch SL, Goff D, Savage CR, Schacter DL, Fischman AJ. et al. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nature Neurosci 1998; 01: 318-323.
121 Meyer-Lindenberg AS, Olsen RK, Kohn PD, Brown T, Egan MF, Weinberger DR. et al. Regionally specific disturbance of dorsolateral prefrontal-hippocampal funcitonal connectivity in schizophrenia. Arch Gen Psychiatry 2005; 62: 379-386.
122 Laruelle M. Imaging dopamine transmission in schizophrenia. A review and meta-analysis. Quarterly J Nucl Med 1998; 42: 211-221.
123 Soares JC, Innis RB. Neurochemical brain imiging investigations of schizophrenia. Biol Psychiatry 1999; 46: 600-615.
124 Crespo-Facorro B, Paradiso S, Andreasen NC, OLeary DS, Watkins GL, Ponto LLB. et al. Recalling word lists reveals “cognitive dysmetria” in schizophrenia: a positron emission tomography study. Am J Psychiatry 1999; 156: 386-392.
125 Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM. et al. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psychiatry 2000; 48: 651-657.
126 Kapur S, Agid O, Mizrahi R, Li M. How antipsychotics work-from receptors to reality. NeuroRx 2006; 03: 10-21.
127 Grunder G, Landvogt C, Vernaleken I, Buchholz HG, Ondracek J, Siessmeier T. et al. The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacol 2006; 31: 1027-1035.
128 Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-977.
129 Keshavan MS, Stanley JA, Pettegrew JW. Magnetic resonance spectroscopy in schizophrenia: methodological issues and findings--part II. Biol Psychiatry 2000; 48: 369-380.
130 Stanley JA, Pettegrew JW, Keshavan MS. Magnetic resonance spectroscopy in schizophrenia: Methodological issues and findings-part I. Biol Psychiatry 2000; 48: 357-368.
131 Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nature Rev Neurosci 2006; 07: 818-827.
132 Bertolino A, Rubino V, Sambataro F, Blasi G, Latorre V, Fazio L. et al. Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype. Biol Psychiatry 2006; 60: 1250-1258.
133 Meyer-Lindenberg A, Kohn PD, Kolachana B, Kippenhan S, Inerney-Leo A, Nussbaum R. et al. Midbrain dopamine and prefrontal function in humans: interaction and modulation by COMT genotype. Nature Neurosci 2005; 08: 594-596.
134 Buckholtz JW, Meyer-Lindenberg A, Honea RA, Straub RE, Pezawas L, Egan MF. et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci 2007; 27: 1584-1593.
135 Callicott JH, Egan MF, Mattay VS, Bertolino A, Bone AD, Verchinksi B. et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry 2003; 160: 709-719.
136 Vogeley K, Tepest R, Pfeiffer U, Schneider-Axmann T, Maier W, Honer WG. et al. Right frontal hypergyria differentiation in affected and unaffected siblings from families multiply affected with schizophrenia: a morphometric mri study. Am J Psychiatry 2001; 158: 494-496.
137 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. ArchGen Psychiatry 1987; 44: 660-669.
138 Meyer-Lindenberg A, Poline JB, Kohn PD, Holt JL, Egan MF, Weinberger DR. et al. Evidence for abnormal cortical functional connectivity during working memory in schizophrenia. Am J Psychiatry 2001; 158: 1809-1817.
139 Reif A, Schmitt A, Lesch KP. Adulte Neurogenese und Schizophrenie – gibt es einen Zusammenhang?. Nervenheilkunde 2007; 26: 368-376.